Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

SLU-PP-332 iconSLU-PP-332Small moleculeNo amino acid sequence. Icon reflects category theme only.

SLU-PP-332

MetabolicResearch
~4-6 hours half-life (estimated)·Injection·4w on / 4w off

Also known as: SLU-PP-332, SLUPP332, SLU PP 332

Mice on SLU-PP-332 ran 45% farther and 70% longer without any extra training. This small-molecule ERR agonist (not actually a peptide) flips on the same metabolic gene programs that aerobic exercise triggers, pushing skeletal muscle toward fatty acid oxidation and oxidative fiber types. All published data come from mouse models; zero human trials exist. The community figured this out before formal research caught up, with 20 to 60 Reddit threads tracking mg-level subcutaneous protocols for endurance and fat loss. Cardiac safety remains the open question, given ERR expression in heart tissue and an NFAT activation signal in one 2024 study [1].

What Is SLU-PP-332?

Twelve percent body weight gone in 28 days, and the mice weren't even running. SLU-PP-332 (CAS pending; developed at Saint Louis University and Washington University School of Medicine) is a synthetic pan-agonist of the estrogen-related receptors ERRalpha, ERRbeta, and ERRgamma. It activates aerobic exercise gene programs without physical activity.

The mechanism is direct. SLU-PP-332 binds the ligand-binding domain of ERRalpha (EC50 = 98 nM) and recruits the coactivator PGC-1alpha. That drives transcription of genes governing mitochondrial biogenesis, fatty acid oxidation, and oxidative phosphorylation. Muscle fibers shift toward the oxidative Type IIa phenotype. Resting energy expenditure climbs within two hours of the first dose in mice.

The numbers from Billon et al. [2] are specific: 25% increase in fatty acid oxidation, 12% body weight reduction in diet-induced obese mice, and fat mass gain reduced roughly 10-fold versus untreated controls. A second study from the same group [3] confirmed 45% greater running distance and 70% longer time to exhaustion. Unlike GLP-1 receptor agonists, SLU-PP-332 does not suppress appetite.

Community adoption runs ahead of the science. Subcutaneous injection at 10 to 50 mg/day is the current standard, though no human pharmacokinetic data exist. All published in vivo data used intraperitoneal injection in mice at 50 mg/kg twice daily. Formal clinical trials have not been initiated.

How SLU-PP-332 Works

SLU-PP-332 is a pan-agonist of the estrogen-related receptors, with highest potency at ERRalpha (EC50 = 98 nM), followed by ERRbeta (EC50 = 230 nM) and ERRgamma (EC50 = 430 nM). It binds a hydrophobic trench adjacent to the ligand-binding domain, interacting with residues Leu345 and Phe377. That stabilizes the receptor in its active conformation.

The downstream cascade starts with PGC-1alpha recruitment. PGC-1alpha is a transcriptional coactivator that amplifies expression of genes controlling mitochondrial biogenesis, fatty acid oxidation, and oxidative phosphorylation. Skeletal muscle responds by shifting fiber composition toward the oxidative Type IIa phenotype, the same adaptation seen after weeks of endurance training.

SLU-PP-332 also induces DDIT4, a negative regulator of mTORC1. This adds an interesting wrinkle; mTOR suppression could theoretically limit anabolic recovery. Bonanni et al. (Frontiers in Physiology, 2025; DOI 10.3389/fphys.2025.1616693) confirmed ERR pathway activation in human myoblasts in vitro, providing the first human-adjacent data. Whole-body energy expenditure increased within two hours of dosing in mouse models.

One concern sits in the cardiac data. Xu et al. (Circulation 2024)[1] found improved ejection fraction and reduced fibrosis in a heart failure mouse model, which looks cardioprotective. The same paper noted NFAT pathway activation in cardiomyocytes. NFAT signaling is a hypertrophic pathway. No cardiac hypertrophy was confirmed at study doses, but the signal warrants monitoring.

SLU-PP-332 Benefits

  • SLU-PP-332 benefits center on metabolic activation and exercise mimicry, with all dose-response data from mouse models.
  • Running endurance jumped 45% in distance and 70% in time to exhaustion after 2 to 3 weeks of dosing (Billon et al.)[3].
  • Fatty acid oxidation increased 25% in treated mice, with resting energy expenditure climbing within two hours of a single dose.
  • Body weight dropped 12% in diet-induced obese mice over 28 days, with fat mass gain reduced roughly 10-fold (Billon et al.)[2]. No appetite suppression involved.
  • Glucose tolerance and insulin sensitivity improved in the same obese mouse models; community users anecdotally report HbA1c and eGFR improvements on bloodwork.
  • Cardioprotective effects observed in a heart failure mouse model: improved ejection fraction and reduced cardiac fibrosis (Xu et al., Circulation 2024)[1].
  • Muscle fiber-type shift toward oxidative Type IIa fibers, the same adaptation endurance athletes build over months of training.

SLU-PP-332: Science vs Community Consensus

Partially Aligned
Scientific Evidence
Weak
Based on 7 key studies·Research only

Preclinical evidence in mice shows increased fat oxidation, reduced body weight, improved endurance, and improved glucose tolerance.

Dosing studied: 50 mg/kg i.p. twice daily in mice (28-day studies); no human equivalent established
Read the evidence (key study, limitations)

Cardioprotective in heart failure mouse model [1]. First human-adjacent data (in vitro myoblasts, Frontiers 2025) confirms ERR pathway activation. Zero human clinical trials. No established safe or effective human dose.

Key Study

Billon et al., ACS Chem Biol 2023 (PMID 36988910): ERR-dependent exercise response; Billon et al., JPET 2024 (PMID 37739806): metabolic syndrome; Xu et al., Circulation 2024 (PMID 37961903): cardiac protection; Bonanni et al., Front Physiol 2025 (DOI 10.3389/fphys.2025.1616693): human myoblasts in vitro

Limitations

All in vivo data from mouse models. Route used in studies (i.p.) is not translatable to humans. No PK/PD data in humans. Long-term toxicity, carcinogenicity, and reproductive safety uncharacterized. NFAT pathway activation in cardiomyocytes noted in Xu et al. 2024: clinical relevance in healthy humans unknown.

Community Experience
Weak
3.5/5
Based on ~20–60 Reddit threads across r/peptides, r/nootropics, r/steroids

Cautious optimism. mg-level SC injection community reports improved endurance, subjective fat loss, and anecdotal bloodwork improvement (LDL, A1C, eGFR).

Community dosing: 10–50 mg/day SC injection (community standard); 250 mcg–2 mg/day oral capsule (low bioavailability, lower confidence)
Read the reports (what users report 4, common issues 5)

Significant early dosing confusion (mcg vs mg) meant many users saw zero effect. Cardiac concern is discussed but not based on confirmed human adverse events.

What users report (4)
  • Cardiovascular endurance enhancement: "cellular energy" distinct from stimulant-based effects
  • Fat loss and body composition improvement without appetite suppression
  • Anecdotal bloodwork improvement: LDL reduction, HbA1c decrease, eGFR gains
  • Improved recovery between training sessions and higher training volume
Common issues (5)
  • Widespread mcg vs mg dosing confusion: mcg-dose users almost universally reported zero effect
  • SC injection site lumps and nodules with suspension/underdissolved powder formulations
  • Oral forms widely considered ineffective at practical mg-level doses due to very low bioavailability
  • Source quality concerns: counterfeit and underdosed supply flagged in community forums
  • WADA anti-doping interest confirmed (2026 metabolite paper): implications for competitive athletes
Partially Aligned

Community protocols directionally follow the mouse mechanism (ERR agonism → fat oxidation + endurance). BSA allometric scaling from 50 mg/kg mouse dose gives theoretical rationale for mg-level SC dosing. However, route (SC vs. i.p.), dose magnitude, and human safety profile are entirely unvalidated. Science is mouse-only; community outcomes cannot be confirmed or denied by published data.

SLU-PP-332 Dosage Guide

SpeculativePreclinical data only: no human dosing data established
LevelDose / InjectionFrequency
Beginner10 mg
DailyTrack
Moderate25 mg
DailyTrack
Aggressive50 mg
DailyTrack
Note:

This is a small molecule, not a peptide. Reconstitution math depends on your vial and solvent choice. SLU-PP-332 dissolves in DMSO or can be reconstituted with bacteriostatic water for subcutaneous injection.

For a 25 mg vial reconstituted with 1 mL bacteriostatic water: concentration is 25 mg/mL. A 10 mg dose is 40 IU on a U100 insulin syringe (0.4 mL). A 25 mg dose uses the full syringe (100 IU / 1.0 mL); consider splitting across two injection sites at that volume.

For a 10 mg vial reconstituted with 0.5 mL: concentration is 20 mg/mL. A 10 mg dose is 50 IU (0.5 mL).

The mcg versus mg confusion tripped up a lot of early adopters. If you're dosing in the 250 to 1,500 mcg range, you're almost certainly too low. Community consensus settled on 10 to 50 mg/day subcutaneous as the effective range. Oral bioavailability is widely described as "nearly useless" for hitting meaningful plasma levels.

Get an ECG before your first cycle. That's the single most important safety step given the cardiac data.

Cycling Protocol

On Period
4 weeks
Off Period
4 weeks

No established cycling protocol for humans. Animal studies used continuous 28-day dosing. Extended use beyond study durations has not been evaluated.

Calculate your SLU-PP-332 dose
Free dosage calculator with syringe visualization

Or use the universal Peptide Calculator for any peptide.

SLU-PP-332 Protocols by Goal

beginnerCommunity4 weeks on, 4 weeks off
Conservative SC protocol
Wk 4
10 mg · Once daily · Subcutaneous injection

Expected: Mouse data: 12% body weight reduction, improved glucose tolerance over 28 days. Community: subtle fat loss, improved metabolic bloodwork (anecdotal only, no controlled human data).

Monitor: Baseline and end-of-cycle: ECG (cardiac monitoring), ALT/AST, lipid panel, HbA1c/fasting glucose

How to Use SLU-PP-332

  1. 1
    Check your vial label

    Common sizes are 10 mg and 25 mg. Verify lot-specific certificate of analysis (COA) with HPLC purity of 99% or higher.

  2. 2
    Add bacteriostatic water slowly

    For a 25 mg vial, add 1 mL. For a 10 mg vial, add 0.5 mL. Swirl gently until fully dissolved. Do not inject if any visible powder or particles remain; injection site lumps come from undissolved material.

  3. 3
    Draw your dose

    For a 10 mg dose from a 25 mg/1 mL vial: draw to 40 IU on a U100 insulin syringe (0.4 mL). For a 25 mg dose from the same vial: draw the full 100 IU (1.0 mL) and consider splitting across two injection sites.

  4. 4
    Step 4

    Inject subcutaneously using a 27 to 29 gauge needle at a 45 degree angle into abdominal or thigh fat. Rotate sites.

  5. 5
    Step 5

    Timing: 60 to 90 minutes before exercise or with your first meal in the morning.

  6. 6
    Store reconstituted solution at 2 to 8 degrees Celsius

    Use within 2 weeks.

  7. 7
    Monitor: ECG at baseline and end of cycle

    Liver enzymes (ALT, AST) and lipid panel at baseline and end of cycle. Stop immediately if you experience palpitations, chest tightness, or shortness of breath.

Alternative Routes

Oral capsule

Consumer products are typically 250–500 mcg/capsule. Achieving 10 mg orally requires 20–40 capsules/day at ~$667–$1,334/day at typical consumer capsule pricing. No published oral bioavailability data in any species.

Community consensus: oral bioavailability is very low: widely described as "nearly useless" for achieving effective plasma levels. All published mouse PK used i.p. administration. Some users report mild effects at 1–2 mg oral; almost universally reported as underdosed vs. SC injection.

Subcutaneous injection

Same mg dose as community standard. Volume challenge: 10 mg dose requires 0.4–1.0 mL depending on reconstitution concentration. No IP-to-SC bioavailability equivalence data.

All published studies used i.p. injection in mice. SC adopted by community as closest feasible human analog. Injection site lumps reported with improper reconstitution. Splitting doses across 2 sites recommended if volume >0.5 mL.

Intraperitoneal

BSA-scaled human equivalent of mouse 50 mg/kg i.p. dose ≈ 650 mg/day for 80 kg human: far above community SC protocols of 10–50 mg/day.

I.P. is standard preclinical methodology. Not appropriate for self-administration. The extreme dose gap between BSA-scaled theoretical equivalent (650 mg) and community practice (10–50 mg) underscores the complete absence of human dose-finding data.

Mixing your own vial? Use the SLU-PP-332 reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

SLU-PP-332 Stacking Protocols

Works With

Avoid

GW501516 (Cardarine)

Community "max metabolic" combination but carries uncharacterized additive cardiovascular and carcinogenic risk. GW501516 was abandoned in human trials after multi-organ tumorigenesis in animal carcinogenicity studies. Combined ERR + PPARδ agonism has not been studied in any model.

mTOR inhibitors (rapamycin, everolimus)

SLU-PP-332 upregulates DDIT4, a negative regulator of mTORC1. Combined mTOR suppression could impair muscle protein synthesis and anabolic recovery.

Rate-controlling cardiac medications (beta-blockers, digoxin, antiarrhythmics)

SLU-PP-332 activates ERRs highly expressed in cardiac tissue. Combined effects on cardiac energy metabolism and rate control are completely unknown. Theoretical arrhythmia risk.

Insulin / sulfonylureas / SGLT2 inhibitors

SLU-PP-332 improves insulin sensitivity and glucose tolerance in animal models. Additive glucose-lowering effect with antidiabetic medications could cause clinically significant hypoglycemia.

Estimated Cost

Generic / Research
Bulk research chemical powder (≥99% HPLC): $32/g (1g), $102/10g ($10.20/g), $560/100g ($5.60/g). At 25mg/day from 100g purchase: ~$0.26/day. Oral consumer capsules: ~$49.99/30 capsules at 250mcg = ~$6.67/mg: not cost-effective for mg-level SC protocols.

Pricing updated 2026-04-09

SLU-PP-332 Side Effects

The most serious concern with SLU-PP-332 is cardiac. ERR receptors are highly expressed in heart tissue, and Xu et al. (Circulation 2024)[1] identified NFAT pathway activation in cardiomyocytes. NFAT is a hypertrophic signaling pathway. No cardiac hypertrophy was observed at study doses in mice, but the clinical relevance in healthy human hearts is entirely unknown. An ECG baseline before starting is not optional for anyone considering this compound.

Zero human safety data exist. That bears repeating: no Phase 1 trial, no formal toxicology in humans, no dose-finding study. Everything below comes from mouse models or community self-reports.

In published animal studies, Billon et al. [2] noted minor elevations in plasma cholesterol and liver enzymes. These were described as relatively minor changes, but "minor" in a 28-day mouse study does not predict what happens in a human over months. Liver function monitoring (ALT, AST) at baseline and end of cycle is the minimum standard.

Long-term toxicity has not been assessed. Carcinogenicity studies have not been conducted. Reproductive safety is completely uncharacterized. The community draws comfort from SLU-PP-332 working through ERR (not PPARdelta like Cardarine/GW501516, which caused multi-organ tumors in animal carcinogenicity studies). That distinction is mechanistically valid but does not constitute a safety endorsement.

Injection site lumps and nodules are the most commonly reported issue in community forums. These result from incomplete reconstitution or suspension formulations not designed for subcutaneous administration. Ensuring complete dissolution before drawing prevents most occurrences. Using a 27 to 29 gauge needle at a 45 degree angle into subcutaneous fat and rotating sites helps.

Source quality is a real problem. Counterfeit and underdosed supply has been flagged across community forums. Consumer oral capsules at mcg doses are not appropriate for mg-level subcutaneous protocols.

Contraindications include pregnancy or breastfeeding (reproductive safety unassessed in any species), liver disease (given the enzyme elevation signal), hormone-sensitive conditions (ERR receptors interact with estrogen-related pathways), and anyone on rate-controlling cardiac medications. Children and adolescents should not use this compound.

When to stop: any new cardiac symptom (palpitations, chest tightness, dyspnea). ALT or AST above 2x the upper limit of normal. Unexplained injection site reactions beyond a transient lump.

Common Issues & Solutions

Zero effect reported: Almost certainly a dosing unit error. Verify you are dosing in mg (10–25 mg), NOT mcg. mcg-range oral protocols are near-universally reported as ineffective. SC injection in the mg range is the community-consensus route.

Injection site lumps or nodules: Caused by undissolved powder (incomplete reconstitution) or suspension formulations not suitable for SC injection. Ensure complete dissolution before drawing. Use 27–29G needle at 45° angle into SC fat. Rotate injection sites.

Cardiac monitoring is not optional: Unlike typical peptides, SLU-PP-332 has high ERR expression in cardiac tissue. An ECG baseline before starting is the single most important safety step given the NFAT activation signal in Xu et al. Circulation 2024 [1].

No established cycling protocol: The 4–8 weeks on / 4–8 weeks off convention is borrowed from GW501516 (Cardarine) community practice with no supporting data for SLU-PP-332. Published mouse studies used continuous 28-day dosing without cycling. Cycling is precautionary, not evidence-based.

Source and dose verification: Bulk powder (≥99% HPLC) is the most cost-effective and quality-verified form. Consumer oral capsules at mcg doses are not cost-effective or practical for mg-level SC protocols.

Ask AI about this page

Ask AI for a second opinion on SLU-PP-332 dosing and side effects

Contraindications

  • Pregnancy or breastfeeding: reproductive safety not assessed in any species
  • No human safety data: contraindications are unknown
  • Known hypersensitivity to SLU-PP-332 or related ERR agonists
  • Liver disease: minor liver enzyme elevations observed in animal studies
  • Hormone-sensitive conditions: ERR receptors interact with estrogen-related pathways
  • Children and adolescents: no developmental safety data available

Drug Interactions

  • Estrogen receptor modulators (SERMs, aromatase inhibitors): potential pathway overlap with estrogen-related receptor signaling
  • Diabetes medications (insulin, metformin, sulfonylureas): may compound glucose-lowering effects based on animal data showing improved insulin sensitivity
  • Lipid-lowering agents (statins, fibrates): potential additive effects on fatty acid metabolism
  • CYP450 substrates: metabolic interaction profile in humans is completely unknown
  • Other exercise mimetics (AICAR, GW501516): theoretical additive metabolic stress

Product Quality

Recommended Monitoring

TestWhenTarget
ECG (12-lead)Baseline before first cycle; end of each cycleNormal sinus rhythm; no new conduction abnormalities or QTc prolongation
Liver enzymes (ALT, AST)Baseline; end of cycleWithin normal limits; hold if >2x ULN
Lipid panel (LDL, HDL, triglycerides)Baseline; end of cycleNot listed
Fasting glucose / HbA1cBaseline; end of cycleNot listed
ECG (12-lead)

ERRs are highly expressed in cardiac tissue. Xu et al. Circulation 2024 (PMID 37961903) noted NFAT pathway activation in cardiomyocytes: a hypertrophic signaling pathway. No hypertrophy confirmed at study doses in animals, but baseline cardiac assessment is the primary safety step.

Liver enzymes (ALT, AST)

Minor liver enzyme elevations observed in animal studies (Billon et al. JPET 2024). No human liver safety data.

Lipid panel (LDL, HDL, triglycerides)

Minor plasma cholesterol changes seen in animal studies. Community anecdotally reports LDL improvement. Monitor for unexpected adverse lipid changes.

Fasting glucose / HbA1c

SLU-PP-332 improves insulin sensitivity in obese mouse models. Monitor for additive hypoglycemia risk in users on antidiabetic medications.

SLU-PP-332 Before and After

Day 1
mouse data

Decreased respiratory exchange ratio observed within 2 hours of first dose, indicating a shift toward fatty acid oxidation over carbohydrate metabolism.

Week 1
mouse data

Measurable increase in energy expenditure and early changes in gene expression related to mitochondrial biogenesis in skeletal muscle tissue.

Weeks 2-3
mouse data

Running endurance improved: mice ran 45% farther and 70% longer. Shift toward Type IIa oxidative muscle fibers becomes detectable.

Week 4
mouse data

12% body weight reduction in obese mice. Fat mass gain reduced by approximately 10-fold compared to untreated controls. Improved glucose tolerance and lower fasting insulin.

What to Expect

Day 1 to 2: Mouse data show a metabolic shift within two hours of the first dose. Respiratory exchange ratio drops, signaling a switch from carbohydrate to fatty acid oxidation. Resting energy expenditure increases. Community users report little to nothing subjectively at this stage; some mention mild warmth or energy. Injection site lumps can occur if reconstitution was incomplete.

Week 1: Mitochondrial biogenesis gene expression ramps up in skeletal muscle (mouse data). Whole-body energy expenditure continues to rise. Community reports start showing subtle improvements in cardiovascular training performance and lower perceived exertion during aerobic work.

Weeks 2 to 3: This is where the mouse endurance data get interesting. Treated mice ran 45% farther and 70% longer than controls. Muscle fiber-type shift toward oxidative Type IIa fibers becomes detectable. Most community users report their peak subjective endurance response in this window: improved aerobic capacity, faster recovery between sessions, higher training volume tolerance.

Week 4: The full metabolic picture emerges in mouse data. Obese mice lost 12% body weight. Fat mass gain was reduced roughly 10-fold. Fasting glucose improved and insulin sensitivity increased. Community users finishing 4-week cycles report anecdotal fat loss and improved bloodwork numbers (LDL, HbA1c, eGFR), though none of these outcomes are confirmed by controlled human studies.

Detailed Timeline: Science vs Community

Day 1–2
Science

Decreased respiratory exchange ratio within 2 hours of first dose in mice: shift from carbohydrate to fatty acid oxidation. Raised resting energy expenditure. (Mouse data only)

Community

No reliable acute subjective effects reported at day 1–2. Some users report mild increase in energy or warmth.

Week 1
Science

Increased mitochondrial biogenesis gene expression in skeletal muscle. Measurable increase in whole-body energy expenditure in mouse models. (Mouse data only)

Community

Subtle improvement in cardiovascular training performance. Reduced perceived exertion during aerobic work reported by some users.

Weeks 2–3
Science

Mice ran 45% farther and 70% longer. Shift toward Type IIa oxidative muscle fibers detectable by week 3. This fiber-type shift is the mechanistic basis for sustained endurance gains. (Mouse data only)

Community

Most users report peak subjective endurance effects in this window. Improved aerobic capacity, faster recovery between sets, higher training volume tolerance.

Week 4
Science

12% body weight reduction in obese mice vs. controls. Fat mass gain reduced ~10-fold. Improved fasting glucose and insulin sensitivity. (Mouse data only)

Community

Anecdotal fat loss and improved bloodwork (LDL, HbA1c, eGFR) reported at end of 4-week cycles. No controlled human data. Weight loss outcomes are not confirmed in human community reports.

Pharmacokinetics

Half-Life
5h
Bioavailability
Unknown in humans; i.p. administration used in all published studies
Tmax
~1-2 hours (estimated from murine plasma levels)
Data Confidence
low

Source: Estimated from murine PK data: plasma exposure 0.2 μM at 6 hours post-dose (30 mg/kg i.p.)

Pharmacokinetics: Active Dose Over Time

t½ = ~4-6 hours (estimated from murine PK)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Who Should Consider SLU-PP-332

  • Research subjects in preclinical metabolic studies
  • Animal models of diet-induced obesity and metabolic syndrome
  • Potential future application: individuals unable to exercise due to disability or chronic illness
  • Potential future application: age-related muscle wasting (sarcopenia)
  • Potential future application: metabolic syndrome and insulin resistance

Related Peptides

What Changed for SLU-PP-332

No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

Peptide Schedule Research TeamReviewed Apr 7, 20266 Citations

References

  1. [1]Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function (Circulation 2024) (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]A Synthetic ERR Agonist Alleviates Metabolic Syndrome (Billon et al., J Med Chem 2023) (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity (ACS Chem Biol 2023) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Store at -20°C, desiccated, protected from light: stable for 12+ months
After Reconstitution
Store at 2-8°C in DMSO or appropriate vehicle, use within 2 weeks
Temperature
-20°C (long-term) or 2-8°C (short-term)

Frequently Asked Questions

Oral bioavailability is very low: community consensus is that it's "nearly useless" for achieving effective plasma levels. All published mouse PK data used intraperitoneal injection. SubQ injection at mg-level doses is the primary community route, though it also has no peer-reviewed validation.

Here's the thing: the mcg-range protocols (250-1,500 mcg) came from confusion with typical peptide dosing conventions and reportedly did nothing for most users. The mg-range protocols (10-50 mg/day SC) are the current community standard, derived from scaling the mouse 50 mg/kg dose down to humans. There is no evidence-based human starting dose.

Community thinks so. Cardarine was abandoned after causing multi-organ tumors in animal carcinogenicity studies. SLU-PP-332 works through ERR (not PPAR-delta) and has no carcinogenicity signal in shorter studies. But long-term carcinogenicity studies haven't been done for SLU-PP-332 either, so it's not a clean safety endorsement.

The data is contradictory. Xu et al. (Circulation 2024, PMID 37961903) showed improved ejection fraction and reduced fibrosis in a heart failure mouse model: looks cardioprotective. But the same paper noted NFAT pathway activation in cardiomyocytes, which is a hypertrophic signaling pathway. Effect on healthy human hearts? Unknown. This is the primary unresolved safety question.

No evidence-based protocol exists. Published mouse studies used 28-day continuous dosing. Community borrows 4-8 weeks on / 4-8 weeks off from Cardarine conventions. All of it is precautionary guesswork, not data-driven.